Gynaecology News and Research

RSS

Highlights on reasoning behind MRC's negative decision on funding of IVF

Thirty-two years ago today, the world's first baby was born after in vitro fertilisation. However, the work that led to the birth of Louise Brown on 25 July 1978 had to be privately funded after the UK's Medical Research Council decided in 1971 against providing the Cambridge physiologist Robert Edwards and the Oldham gynaecologist Patrick Steptoe with long-term financial support. Today, an intriguing paper published in Europe's leading reproductive medicine journal Human Reproduction reveals for the first time the reasoning behind the MRC's much-criticised decision.

26 Jul 2010

Vaginal birth after previous C-section may be a safe option say doctors

According to new practice guidelines revealed for obstetricians by the American College of Obstetricians and Gynecologists this Wednesday, a vaginal birth after a Caesarean section (VBAC) or maybe even after two C-sections can be a safe and appropriate choice.

21 Jul 2010

Rottapharm Madaus, Selvita sign drug discovery services contract

Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

20 Jul 2010

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

Rubicon Genomics today announced that its PicoPlex linear whole genome amplification technology was proven to be effective in an independent clinical study organized by the European Society for Human Reproduction and Embryology. At a press conference during its 26th Annual Meeting in Rome, ESHRE reported the success of its "groundbreaking proof of principle study" showing that a new approach incorporating PicoPlex could more accurately detect and characterize chromosomal abnormalities in human eggs.

1 Jul 2010

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

A new, effective, non-surgical treatment for uterine fibroids can help women with this condition maintain their fertility, an American scientist told the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Wednesday).

30 Jun 2010

Study evaluates potential risks and benefits of moderate alcohol consumption

A discussion by renowned epidemiologist Kenneth Mukamal has recently been published in the Journal of the American Medical Association, JAMA. It provides a discussion in response to a theoretical question, - if you are a 42 year old male, should you drink alcohol ( in moderation) for your health?

30 Jun 2010

Better test to predict menopause on the horizon

With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.

28 Jun 2010

Researchers review data comparing IUDs and hormonal contraceptives

Women who have had intrauterine devices fitted as contraceptives are less likely to become pregnant than those who have hormone injections, a new review by Cochrane Researchers has found. The review, which focused on women in developing countries, also found a possible link between contraceptive method and disease progression in HIV.

19 Jun 2010

Reprogrammed killer cells prevent metastasis

A team of researchers has developed a method to produce cells that kill tumour cells in the lab and prevent tumours forming in mouse models of cancer. Although the current work is in cells and mouse, if the research transfers to human biology, the new type of cell could be a new source for cell-based anticancer therapies.

11 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Most Canadians would describe sexual desire as feelings of longing, craving, satisfying a sensuous appetite, or even the need for sensual indulgence. Today, the Society of Obstetricians and Gynaecologists of Canada wants to explain that desire is more than just a "feeling". The SOGC wants Canadian women to better understand the physical and psychosocial causes that may predispose to, precipitate or maintain a loss of desire.

5 Jun 2010

SOGC urges strategy for preventing deaths during delivery, childbirth

As the G8 approaches, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is urging the Canadian government to recognize that a strategy on maternal and child health must focus on preventing deaths during delivery and childbirth as 80% of maternal deaths in low-resource countries take place at that time.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Results of a subanalysis from the FAIR-HF study demonstrate that correcting iron deficiency with Ferinject (ferric carboxymaltose) can improve renal function in chronic heart failure patients. Ferinject is an intravenous iron product used to treat iron deficiency and iron deficiency anaemia.

From CSL Ltd 31 May 2010

Advances in women's health, practice of obstetrics and gynaecology to be discussed at SOGC

The 66th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada. Leading international and Canadian experts will meet to discuss the latest knowledge and advances in women's health and in the practice of obstetrics and gynaecology.

29 May 2010

CPC seminar to explore new rules shaping pregnancy, pregnancy planning

The transformation of pregnancy into a time of expert-led 'training' for potential parents will be discussed and criticised at the final Changing Parenting Culture seminar at the University of Kent's Canterbury campus 22-23 June.

27 May 2010

Simbionix USA to launch two new hands-on training systems at AUA annual meeting

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is launching two new hands-on training systems - the Lap Nepherctomy simulation module and the VirtaMed TURPSim. Both solutions will be revealed for the first time at the AUA annual meeting in San Francisco next week.

25 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin

Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.

19 May 2010